Immune globulin - Nihon Pharmaceutical

Drug Profile

Immune globulin - Nihon Pharmaceutical

Alternative Names: Immunoglobulin intravenous - Nihon Pharmaceutical; Kenketu Glovenin-I; Kenketu Glovenin-I-Nichiyaku; NPB-01

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nihon Pharmaceutical
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Agammaglobulinaemia; Chronic inflammatory demyelinating polyradiculoneuropathy; Pemphigus; Stevens-Johnson syndrome; Toxic epidermal necrolysis
  • Phase III Bullous pemphigoid; Guillain-Barre syndrome; Motor neuron disease
  • Phase II Neuromyelitis optica

Most Recent Events

  • 01 Sep 2015 Nihon Pharmaceutical completes a phase III trial for Chronic inflammatory demyelinating polyradiculoneuropathy in Japan (NCT01824251)
  • 01 Jun 2015 Nihon Pharmaceutical completes a phase III trial for Motor neuron disease in Japan (NCT01827072)
  • 01 Jun 2014 Nihon Pharmaceutical completes a phase III trial in Stevens-Johnson syndrome and Toxic epidermal necrolysis in Japan (NCT01696500)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top